We’re seeing lots of movement when it comes to COVID-19 treatments. (1/4)
1
1
1
Replies
Recent data released on Merck’s Molnupiravir shows the drug appeared to cut the risk of COVID-19 hospitalization and death by 50 percent. https://t.co/dlO73FrUQU (2/4)
1
0
1
AstraZeneca’s Monoclonal antibody cocktail AZD7442 also appeared to reduce the risk of severe disease or death by 50 percent in patients who were treated within seven days of developing symptoms. https://t.co/4R2yISrNhy (3/4)
1
0
1
More to come on therapies. In the meantime, we need to continue to focus on getting people vaccinated to prevent severe illness in the first place. Learn more about vaccines here: https://t.co/MR0Yxu6lGe (4/4)
0
0
1